Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties

US10011615B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Amjad Ali · Freehold, US
• Michael Man-Chu Lo · Rahway, US
• Yeon-Hee Lim · South San Francisco, US
• Andrew Stamford · Madison, US
• Rongze Kuang · Green Brook, US
• Paul Tempest · Brookline, US
• Younong Yu · East Brunswick Township, US
• Xianhai Huang · Hackettstown, US
• Timothy J. Henderson · Natick, US
• Jae-Hun Kim · Scotch Plains, US
• Christopher W. Boyce · Flemington, US
• Pauline C. Ting · New Providence, US
• Junying Zheng · New Providence, US
• Edward Metzger · Edison, US
• Nicolas Zorn · Durmenach, FR
• Dong Xiao · Hackettstown, US
• Gioconda V. Gallo · Summit, US
• Walter Won · Alpine, US
• Heping Wu · Edison, US
• Qiaolin Deng · Edison, US

Key dates

• Filing date: Feb 2, 2017
• Grant date: Jul 3, 2018
• Expiry date: Feb 2, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are compounds of Formula G1: where “RG3”. “Rd1” to “Rd4”, “n”, “m”, “p”, “W”, “X”, “Y”, and “Z” are defined herein, which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2A receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.